Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,361 across all filing types
Latest filing 2024-04-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业2023年度独立董事述职报告（刘俊彦）
Regulatory Filings
2024-04-25 Chinese
亚宝药业董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange. It evaluates the independence of specific directors for the year 2023 and confirms compliance with relevant independence rules. This type of document relates to governance and board oversight rather than financial results, voting, or other categories. It is not a full annual report, audit report, or earnings release. It fits best under Governance Information (CGR) as it details board governance practices and compliance with independence requirements.
2024-04-25 Chinese
亚宝药业集团股份有限公司关于股份回购实施结果暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 亚宝药业集团股份有限公司 regarding the implementation results of a share repurchase program and the subsequent share cancellation. It details the number of shares repurchased, the price range, the total amount spent, approvals, and the impact on share capital. The document does not contain financial statements or detailed financial analysis but focuses on the share buyback transaction and its completion. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-04-23 Chinese
亚宝药业集团股份有限公司关于全资子公司取得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its wholly-owned subsidiary obtaining a drug registration certificate from the national drug regulatory authority. It details the drug name, specifications, approval, and some market information. The document is short (1130 characters) and focuses on regulatory approval news rather than financial data or management discussion. It does not contain financial statements, earnings data, or management reports. It is not a report itself but an announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-15 Chinese
亚宝药业集团股份有限公司关于控股股东部分股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the release of a portion of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the remaining pledged shares, and the shareholder's total holdings. There is no financial report, earnings data, or management discussion. The content focuses on share pledge status, which relates to capital structure changes but specifically concerns share pledge release rather than new financing or capital raising. This fits best under the category of Share Issue/Capital Change (SHA), which includes announcements about capital changes such as share pledges or releases.
2024-04-08 Chinese
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 亚宝药业集团股份有限公司. It details the approval of the share buyback plan, the increase in the buyback amount, and the actual progress of shares repurchased up to a certain date. The document does not contain financial statements or detailed financial analysis but focuses on the update of the share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-04-01 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.